Form 4 for PLX Protalix BioTherapeutics, Inc.

Accepted 2025-09-04 00:00:00 ET · period of report 2025-09-03 · accession 0001415889-25-023705 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2025-09-04	2025-09-03	PLX	Boudes Pol F	Dir	A - Grant	—	+7,500	7,500	New	—
D	2025-09-04	2025-09-03	PLX	Boudes Pol F	Dir	A - Grant	$0.00	+15.0K	15.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-09-03	A	A	7,500	—	7,500	I By Trust	—	—	(F1) Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant. (F2) To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee.
2	Derivative	Stock Options (Right to Buy)	2025-09-03	A	A	15,000	$0.00	15,000	D	$1.64 · — to 2035-09-03	15,000 Common Stock	(F4) Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033. (F3) The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.